Shield Therapeutics (LON:STX) Stock Price Up 9.4% – Here’s Why

Shield Therapeutics plc (LON:STX)’s share price rose 9.4% during trading on Tuesday . The company traded as high as GBX 3.07 ($0.04) and last traded at GBX 2.90 ($0.04). Approximately 909,442 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 4,498,458 shares. The stock had previously closed at GBX 2.65 ($0.03).

Shield Therapeutics Price Performance

The company has a market capitalization of £22.68 million, a price-to-earnings ratio of -65.00 and a beta of 1.42. The stock’s 50-day simple moving average is GBX 3.83 and its two-hundred day simple moving average is GBX 2.98. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.

Shield Therapeutics Company Profile

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.